This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Alkaabi JM, Mushtaq A, Al-Maskari FN, Moussa NA, Gariballa S (2010) Hypokalemic periodic paralysis: a case series, review of the literature and update of management. Eur J Emerg Med 17:45–47
Allenbach Y, Benveniste O (2013) Acquired necrotizing myopathies. Curr Opin Neurol 26:554–560
Anderson K, Bloomer J, Bonkovsky H, Kushner J, Pierach C, Pimstone N, Desnick R (2005) Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142:439–450
Arnon S, Schechter R, Maslanka S, Jewell N, Hatheway C (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462–471
Benatar M, Kaminski H (2006) Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev CD005081
Bloch S, Polkey MI, Griffiths M, Kemp P (2012) Molecular mechanisms of intensive care unit‐acquired weakness. Eur Respir J 39:1000–1011
Bolton C (2005) Neuromuscular manifestations of critical illness. Muscle Nerve 32:140–163
Buttmann M, Kaveri S, Hartung HP (2013) Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci 34:445–457
Carstens PO, Schmidt J (2014) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 175:425–438
Cavalcante P, Bernasconi P, Mantegazza R (2012) Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 25:621–629
Chalela JA (2001) Pearls and pitfalls in the intensive care management of Guillain‐Barre syndrome. Semin Neurol 21:399–405
Chavada G, Willison HJ (2012) Autoantibodies in immune‐mediated neuropathies. Curr Opin Neurol 25:550–555
Chawla J, Gruener G (2010) Management of critical illness polyneuropathy and myopathy. Neurol Clin 28:961–977
Cherington M (2004) Botulism: update and review. Semin Neurol 24:155–163
Dalakas MC (2013) Pathophysiology of autoimmune polyneuropathies. Presse Med 42:e181–e192
de Letter M, Schmitz P, Visser L, Verheul F, Schellens R, de Op Coul D, van der Meché F (2001) Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29:2281–2286
Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G (2007) Clinical comparison of anti‐MuSK‐ vs anti‐AChR‐positive and seronegative myasthenia gravis. Neurology 68:609–611
Dillon F (2004) Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 24:83–94
Dimachkie MM, Barohn RJ (2013) Guillain‐barré syndrome. Curr Treat Options Neurol 15:338–349
Díaz-Manera J, Rojas García R, Illa I (2012) Treatment strategies for myasthenia gravis: an update. Expert Opin Pharmacother 13:1873–1883
Eikermann M, Koch G, Gerwig M, Ochterbeck C, Beiderlinden M, Koeppen S, Neuhäuser M, Peters J (2006) Muscle force and fatigue in patients with sepsis and multiorgan failure. Intensive Care Med 32:251–259
Engel W, Askanas V (2006) Inclusion‐body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66:S20–S29
Engstrom J (2004) Myasthenia gravis: diagnostic mimics. Semin Neurol 24:141–147
Fontaine B, Fournier E, Sternberg D, Vicart S, Tabti N (2007) Hypokalemic periodic paralysis: a model for a clinical and research approach to a rare disorder. Neurotherapeutics 4:225–232
Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:CD002277
Gilchrist J (2002) Overview of neuromuscular disorders affecting respiratory function. Semin Respir Crit Care Med 23:191–200
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA (2011) Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 847393
Gilhus NE (2012) Myasthenia and the neuromuscular junction. Curr Opin Neurol 25:523–529
Goodman B, Boon A (2008) Critical illness neuromyopathy. Phys Med Rehabil Clin N Am 19:97–110 (vii)
Green D (2005) Weakness in the ICU: Guillain‐Barré syndrome, myasthenia gravis, and critical illness polyneuropathy/myopathy. Neurologist 11:338–347
Guptill JT, Oakley D, Kuchibhatla M, Guidon AC, Hobson-Webb LD, Massey JM, Sanders DB, Juel VC (2013) A retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle Nerve 47:170–176
Gutmann L, Blumenthal D, Schochet S (1996) Acute type II myofiber atrophy in critical illness. Neurology 46:819–821
Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV (2001) Preceding infections, immune factors, and outcome in Guillain‐Barre syndrome. Neurology 56:758–765
Hain B, Jordan K, Deschauer M, Zierz S (2006) Successful treatment of MuSK antibody‐positive myasthenia gravis with rituximab. Muscle Nerve 33:575–580
Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC (2012) Guillain‐Barré syndrome after exposure to influenza. Nervenarzt 83:714–730
Henderson R, Sandroni P, Wijdicks E (2005) Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol 252:1235–1237
Howard RS, Tan SV, Z’Graggen WJ (2008) Weakness on the intensive care unit. Pract Neurol 8:280–295
Hsieh M, Lyu R, Chang W, Chang K, Chen C, Chang H, Wu Y, Chen S, Ro L (2008) Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol 15:559–564
Hughes RA, Cornblath DR (2005) Guillain‐Barre syndrome. Lancet 366:1653–1666
Hughes R, Donofrio P, Bril V, Dalakas M, Deng C, Hanna K, Hartung H, Latov N, Merkies I, van Doorn P (2008) Intravenous immune globulin (10 % caprylate‐chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo‐controlled trial. Lancet Neurol 7:136–144
Hughes RA, Swan AV, van Doorn PA (2012) Intravenous immunoglobulin for Guillain‐Barré syndrome. Cochrane Database Syst Rev 7:CD002063
Hughes RA, van Doorn PA (2012) Corticosteroids for Guillain‐Barré syndrome. Cochrane Database Syst Rev 8:CD001446
Hughes RA, Pritchard J, Hadden RD (2013) Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome. Cochrane Database Syst Rev 2:CD008630
Hund EF, Borel CO, Cornblath DR, Hanley DF, McKhann GM (1993) Intensive management and treatment of severe Guillain‐Barre syndrome. Crit Care Med 21:433–446
Hund E (2001) Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248:929–934
Jander S, Hartung HP (2006) Aktuelle Aspekte in der Pathogenese, Diagnostik und Therapie der Myasthenia gravis. Akt Neurol 32:3–9
Judemann K, Lunz D, Zausig YA, Graf BM, Zink W (2011) Intensive care unit‐acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy. Anaesthesist 60:887–901
Keogh M, Sedehizadeh S, Maddison P (2011) Treatment for Lambert‐Eaton myasthenic syndrome. Cochrane Database Syst Rev CD003279
Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system. Muscle Nerve 30:131–156
Kieseier B, Meyer Zu Hörste G, Lehmann H, Gold R, Hartung H (2008) Intravenous immunoglobulins in the treatment of immune neuropathies. Curr Opin Neurol 21:555–562
Kieseier BC, Lehmann HC, Meyer Zu Hörste G (2012) Autoimmune diseases of the peripheral nervous system. Autoimmun Rev 11:191–195
Koller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating neuropathy. N Engl J Med 352:1343–1356
Koneczny I, Cossins J, Vincent A (2014) The role of muscle‐specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 224:29–35
Kress JP, Hall JB (2014) ICU‐acquired weakness and recovery from critical illness. N Engl J Med 370:1626–1635
Kung A (2006) Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 91:2490–2495
Kuwabara S, Yuki N (2013) Axonal Guillain‐Barré syndrome: concepts and controversies. Lancet Neurol 12:1180–1188
Latronico N, Rasulo FA (2010) Presentation and management of ICU myopathy and neuropathy. Curr Opin Crit Care 16:123–127
Latronico N, Tomelleri G, Filosto M (2012) Critical illness myopathy. Curr Opin Rheumatol 24:616–622
Lazarou IN, Guerne PA (2013) Classification, diagnosis and management of idiopathic inflammatory myopathies. J Rheumatol 40:550–564
Lefaucheur J, Nordine T, Rodriguez P, Brochard L (2006) Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 77:500–506
Lehmann HC, Hartung HP, Hetzel GR, Kieseier BC (2007aa) Plasma exchange as a therapeutic option in neurological disorders. Nervenarzt 78:168–170 (166, 172–166)
Lehmann HC, Kohne A, zu Horste GM, Kieseier BC (2007bb) Incidence of Guillain‐Barre syndrome in Germany. J Peripher Nerv Syst 12:285
Lehmann H, Hartung H (2008) Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies. Brain 131:1168–1170
Lehmann HC, Meyer zu Hörste G, Hartung HP (2009) Pathogenesis and treatment of immune‐mediated neuropathies. Ther Adv Neurol Dis 2:261–281
Lehmann HC, Hughes RA, Kieseier BC, Hartung H-P (2012) Recent developments and future directions in Guillain‐Barré syndrome. Journal Peripheral Nervous System (in press)
Lynn D, Woda R, Mendell J (1994) Respiratory dysfunction in muscular dystrophy and other myopathies. Clin Chest Med 15:661–674
Maciel RM, Lindsey SC, da Dias Silva MR (2011) Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol 7:657–667
Maddison P, Newsom-Davis J (2003) Treatment for Lambert‐Eaton myasthenic syndrome. Cochrane Database Syst Rev CD003279
Marinelli WA, Leatherman JW (2002) Neuromuscular disorders in the intensive care unit. Crit Care Clin 18:915–929
Mehndiratta MM, Pandey S, Kuntzer T (2011) Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev CD006986
Meyer zu Horste G, Hartung HP, Kieseier BC (2007) From bench to bedside‐‐experimental rationale for immune‐specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 3:198–211
Mukerji S, Aloka F, Farooq M, Kassab M, Abela G (2009) Cardiovascular complications of the Guillain‐Barré syndrome. Am J Cardiol 104:1452–1455
Müllges W, Toyka KV, Hartung H (1994) Acute muscular weakness. In: Hacke W, Hanley DF (Hrsg) Neurocritical Care. Berlin, S 307–320
Palmer K (2006) Abdominal pain due to acute intermittent porphyria: when is the sound of hoof‐beats not horses, but zebras? A case report. Dimens Crit Care Nurs 25:103–109
Pati S, Goodfellow J, Iyadurai S, Hilton-Jones D (2008) Approach to critical illness polyneuropathy and myopathy. Postgrad Med J 84:354–360
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT (2012) Evidence‐based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78:1009–1015
Press R, Mata S, Lolli F, Zhu J, Andersson T, Link H (2001) Temporal profile of anti‐ganglioside antibodies and their relation to clinical parameters and treatment in Guillain‐Barre syndrome. J Neurol Sci 190:41–47
Rabinstein A (2005) Update on respiratory management of critically ill neurologic patients. Curr Neurol Neurosci Rep 5:476–482
Raja Rayan DL, Hanna MG (2010) Skeletal muscle channelopathies: nondystrophic myotonias and periodic paralysis. Curr Opin Neurol 23:466–476
Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain‐Barre syndrome. J Neurol Neurosurg Psychiatry 83:711–718
Raju R, Dalakas M (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887–1896
Raphaël JC, Chevret S, Hughes RA, Annane D (2012) Plasma exchange for Guillain‐Barré syndrome. Cochrane Database Syst Rev 7:CD001798
Rezania K, Goldenberg FD, White S (2012) Neuromuscular disorders and acute respiratory failure: diagnosis and management. Neurol Clin 30:161–185 (viii)
Saperstein D, Barohn R (2004) Management of myasthenia gravis. Semin Neurol 24:41–48
Schneider-Gold C, Hartung H, Gold R (2006) Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34:284–291
Sederholm BH (2010) Treatment of acute immune‐mediated neuropathies: Guillain‐Barré syndrome and clinical variants. Semin Neurol 30:365–372
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of guillain‐barré syndrome: a systematic review and meta‐analysis. Neuroepidemiology 36:123–133
Shahrizaila N, Yuki N (2013) Bickerstaff brainstem encephalitis and Fisher syndrome: anti‐GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 84:576–583
Spillane J, Higham E, Kullmann DM (2012) Myasthenia gravis. BMJ 345:8497
Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard RS (2014) Myasthenia gravis ‐ treatment of acute severe exacerbations in the intensive care unit results in a favourable long‐term prognosis. Eur J Neurol 21:171–173
Stangel M, Hartung H, Gold R, Kieseier B (2009) The significance of intravenous immunoglobulin in treatment of immune‐mediated polyneuropathies. Nervenarzt 80:678–687
Thomas C, Mayer S, Gungor Y, Swarup R, Webster E, Chang I, Brannagan T, Fink M, Rowland L (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260
van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC (2013) Mortality in Guillain‐Barre syndrome. Neurology 80:1650–1654
van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain‐Barre syndrome. Lancet Neurol 7:939–950
Wijdicks E, Henderson R, McClelland R (2003) Emergency intubation for respiratory failure in Guillain‐Barré syndrome. Arch Neurol 60:947–948
Winer JB (2011) Guillain‐Barré syndrome: clinical variants and their pathogenesis. J Neuroimmunol 231:70–72
Yeh J, Chen W, Chiu H (2003) Predicting the course of myasthenic weakness following double filtration plasmapheresis. Acta Neurol Scand 108:174–178
Yuki N, Hartung HP (2012) Guillain‐Barré syndrome. N Engl J Med 366:2294–2304
Yuki N, Odaka M (2005) Ganglioside mimicry as a cause of Guillain‐Barre syndrome. Curr Opin Neurol 18:557–561
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hartung, HP., Lehmann, H.C., Kieseier, B.C. (2015). Neuromuskuläre Erkrankungen bei Intensivpatienten. In: Marx, G., Muhl, E., Zacharowski, K., Zeuzem, S. (eds) Die Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54953-3_48
Download citation
DOI: https://doi.org/10.1007/978-3-642-54953-3_48
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54952-6
Online ISBN: 978-3-642-54953-3
eBook Packages: Medicine (German Language)